Wednesday, Mar 27, 2019
WALLINGFORD, CONNECTICUT AND CHICAGO, ILLINOIS, March 27, 2019 - Gaylord Specialty Healthcare, a not-for-profit long-term acute care hospital in Wallingford, CT and Quest Diagnostics (NYSE: DGX), the ... read more
WALLINGFORD, CONNECTICUT AND CHICAGO, ILLINOIS, March 27, 2019 - Gaylord Specialty Healthcare, a not-for-profit long-term acute care hospital in Wallingford, CT and Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic services based in Chicago, have initiated a joint research collaboration to provide state-of-the-art population health analytics in support of ongoing research at Gaylord Specialty Healthcare.
Peter Grevelding, PT, MSPT, NCS, Vice President, Clinical Operations of Gaylord Specialty Healthcare said that the collaboration was a natural extension of the hospital’s years-long relationship with Quest as the hospital’s in-house provider of diagnostic services. He said that the partnership will benefit both Gaylord and Quest by “advancing clinical practice and knowledge, and help create more advanced integration between diagnostics and treatment.”
“This is a highly synergistic opportunity between Gaylord’s patient-first focus and Quest Diagnostics’ mission of empowering better health with diagnostic insight,” he explained.
Grevelding said that all studies involving Gaylord patients will be designed in conjunction with Quest and reviewed by the hospital’s own Institutional Review Board. Patients will have the opportunity to review the studies before choosing to participate. He said that all patient information used in research will be de-identified.
“Consumers are more engaged in their health than ever before and healthcare innovation is happening at every corner, opening a whole new world for evidence-based diagnostics that may be broadly scaled across hospitals and clinics for real-world implementation,” he said.
Stewart Rosenberg, Consultant to Gaylord Specialty Healthcare and President, Founder and CEO of Bio-Investigations Ltd. for over thirty years and a veteran in the pharmaceutical industry for over forty years, commented on the collaboration: "A focus within Quest Diagnostics of utilizing diagnostic insights toward empowering better health blends nicely with the activities at Gaylord Specialty Healthcare on patient-centricity. We are optimistic about the potential discoveries and benefits of this collaborative effort."
Quest Diagnostics maintains a pipeline of early-stage genetic and biological markers in cardiometabolic disorders with the potential for future diagnostic services for clinical use and pharmaceutical research. Additionally, Quest Diagnostics’ deep biomarker expertise and a rich dataset of de-identified laboratory testing on millions of patients are expected to transform ongoing Gaylord research.
About Gaylord Specialty Healthcare
Gaylord Specialty Healthcare is a rehabilitation-focused, not-for-profit health system that provides inpatient and outpatient care for people at every point in their journey from illness and injury to maximum recovery.
Gaylord Specialty Healthcare is widely recognized for its leadership in treating spinal cord and brain injuries and is also known for treating pulmonary, cardiac, amputee and stroke patients as well as sports-related injuries. It is the only rehabilitation system in CT accredited by CARF (Commission on Accreditation of Rehabilitation Facilities) for both inpatient and outpatient programs. www.gaylord.org
About Quest Diagnostics
Quest Diagnostics empowers people to act to improve health outcomes. Derived from a robust research and development program and the world's largest database of clinical lab results, Quest’s diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and its 45,000 employees understand that, in the right hands and with the right context, Quest’s diagnostic insights can inspire actions that transform lives. More information at www.QuestDiagnostics.com
For more information, please contact Tara Knapp, Vice President of Development, Public Relations and Marketing, Gaylord Specialty Healthcare (203) 284-2838.
Certain statements in this press release constitute forward-looking statements, are not historical facts, and involve risks and uncertainties that could cause actual results to differ from those expected and projected. Such risks and uncertainties may include, but are not limited to (i) general economic conditions; (ii) conditions specific to the industry; (iii) an ability to develop or acquire new technology or products through licensing, merger or acquisition and to obtain regulatory approval to commercialize diagnostic, therapeutic or preventative products; (iv) the effectiveness and ultimate market acceptance of any such products; (v) limitations on third-party reimbursements with respect to any such products; and (vi) competition. Gaylord does not undertake to update or revise any forward-looking statements contained herein whether as a result of new information, future events or otherwise.